700
Participants
Start Date
June 13, 2013
Primary Completion Date
January 1, 2014
Study Completion Date
January 9, 2014
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI
The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
Placebo DISKUS
Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
Placebo NDPI
Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
GSK Investigational Site, Reiger Park
GSK Investigational Site, Kløfta
GSK Investigational Site, Hamar
GSK Investigational Site, Durban
GSK Investigational Site, Stavanger
GSK Investigational Site, Trondheim
GSK Investigational Site, Somerset West
GSK Investigational Site, Mowbray
GSK Investigational Site, Gatesville
GSK Investigational Site, Bodø
GSK Investigational Site, Bloemfontein
GSK Investigational Site, México DF
GSK Investigational Site, Newport News
GSK Investigational Site, Charlotte
GSK Investigational Site, Union
GSK Investigational Site, Greenville
GSK Investigational Site, Easley
GSK Investigational Site, Seneca
GSK Investigational Site, DeLand
GSK Investigational Site, Guadalajara
GSK Investigational Site, St Louis
GSK Investigational Site, Monterrey
GSK Investigational Site, Monterrey
GSK Investigational Site, Oaxaca City
GSK Investigational Site, Coeur d'Alene
GSK Investigational Site, Tucson
GSK Investigational Site, Riverside
GSK Investigational Site, Newport Beach
GSK Investigational Site, Medford
GSK Investigational Site, Renton
GSK Investigational Site, Moscow
GSK Investigational Site, Yaroslavl
GSK Investigational Site, Yaroslavl
GSK Investigational Site, Yaroslavl
GSK Investigational Site, Arkhangelsk
GSK Investigational Site, Ivanovo
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Craiova
GSK Investigational Site, Voronezh
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Saratov
GSK Investigational Site, Izhevsk
GSK Investigational Site, Ulyanovsk
GSK Investigational Site, Chelyabinsk
GSK Investigational Site, Vladimir
GSK Investigational Site, Comuna Alexandru Cel Bun
GSK Investigational Site, Yekaterinburg
GSK Investigational Site, Focşani
GSK Investigational Site, Yekaterinburg
GSK Investigational Site, Omsk
GSK Investigational Site, Chita
GSK Investigational Site, Vladivostok
GSK Investigational Site, Brăila
GSK Investigational Site, Constanța
GSK Investigational Site, Talca
GSK Investigational Site, Concepción
GSK Investigational Site, Talcahuano
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Puente Alto - Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Charleston
GSK Investigational Site, Temuco
GSK Investigational Site, Bergen
GSK Investigational Site, Bucharest
GSK Investigational Site, Bucharest
GSK Investigational Site, Barnaul
GSK Investigational Site, Smolensk
GSK Investigational Site, Tomsk
GSK Investigational Site, Meyerspark
GSK Investigational Site, Die Wilgers
Lead Sponsor
GlaxoSmithKline
INDUSTRY